News | August 16, 2022
Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Subscribe To Our Newsletter & Stay Updated
